Day 4 #ASCO25 Highlights: 1. #DestinyBreast09: 1L TDXd Her2+ MBC 2. #SOFT/TEXT: Adj endo breast ca 3. #CM816: NeoAdj Nivo/chemo NSCLC 4. #NeoADAURA: NeoAdj Osi mEGFR NSCLC 5. #DeLLphi304: 2L Tarla SCLC 6. #IMForte: 1L maint Lurbi ES-SCLC 7. Timings for IO ASCO 1/8

🕒 First phase 3 RCT on time-of-day of immunochemotherapy in stage IIIC–IV #NSCLC (N=210) ✅ Non-invasive, cost-free intervention ✅ Consistent benefit across subgroups ✅ Immune biomarker correlation (CD8⁺↑) ✍️ Awaiting peer-reviewed publication Zhang et al.

No surgery. No recurrence. In this phase 2 trial (n=50), selected patients with HER2+ or TNBC who had pCR after neoadjuvant therapy skipped breast surgery. With 5 years of follow-up: 🟡0% ipsilateral recurrence 🟡100% DFS & OS A bold signal toward surgical de-escalation. Looking

Encorafenib, Cetuximab, and mFOLFOX6 in BRAF-Mutated Colorectal Cancer NEJM doi.org/10.1056/NEJMoa… 🔎BREAKWATER phs-3 👉Impressive OS of 30 months in BRAF mutant CRC 🧐Without any doubts the new SOC in 1st line

C-POST Trial ⚠️High-risk cutaneous SCC-> Surgery + Postop RT-> 1:1 Adjuvant cemiplimab 🆚 Placebo Cemi-> 350 mg Q3w x4, then 700 mg Q6w x6 ✅ 24 mo DFS 87% 🆚 64%, HR=0.32 ✅ DFS benefit across all subgroups ‼️G>=3 TRAEs 9.8% Clearly practice changing✅ #ASCO2025

Happy to see Taha Koray Sahin 's achievements! He is such a diligent and humble young medical oncologist who will drive the future of oncology! Keep going Koray, so much yet to do! ASCO OncoAlert Deniz Can Guven

Practice Point: If more than 6 weeks have passed since the last pertuzumab dose, a reloading dose of 840 mg should be administered. This is particularly relevant in the perioperative setting, where pertuzumab scheduling requires careful attention. For trastuzumab, a reloading

🚨 Our new study alert! Elsevier What is the role of comorbidity burden in response to immunotherapy based combos in patients with metastatic renal cell carcinoma? 🎯Endpoints : Overall surival and time to treatment failure High comorbidity 🟰 Worse Outcomes ❓❗️No

Our new study Ömer Dizdar Deniz Can Guven Mert TOKATLI Taha Koray Sahin ✨️✨️✨️ Prognostic value of serum albumin-creatinine ratio as a biomarker in patients treated with immune checkpoint inhibitors: Immunotherapy tandfonline.com/doi/full/10.10…

📢 RCT in High-Risk Nasopharyngeal Carcinoma (NPC) 👥 324 pts with stage T1-4N2-3M0 NPC + high EBV DNA 🧪 Compared: ➡️ Induction chemo (TPF) ➕ CCRT vs ➡️ CCRT ➕ adjuvant PF chemo 📊 3-yr PFS: 🔹 Induction–CCRT: 73.5% 🔹 CCRT–adjuvant: 70.4% (NS difference, HR 0.86, P = .45)

LEANOX Trial – Lean Body Mass–Based Oxaliplatin Dosing in Stage III Colon Cancer - Emre Yekedüz oncodaily.com/blog/emre-yeke… #ColonCancer #CRC #Cancer #OncoDaily #Medicine #Oncology #MedEd #MedX #MedNews

Submitting a paper 1994: “We’re young, bold, and full of hypotheses.” 2025: “We’ve aged, revised 7 times, survived 3 rejections, and still smiling.” #AcademicPublishing

🚨 Just out in Red Journal! We analyzed our 191-patient H&N reirradiation cohort, with a specific focus on toxicity and CBOS 📊 Real-world SBRT data 🧑‍⚕️ Lessons on patient selection & risk mitigation redjournal.org/article/S0360-… IJROBP - The Red Journal Gozde Yazici Alper Kahvecioglu MD Ecem Yigit

🆕Our latest study is now out in Immunotherapy! 🧠The albumin–myosteatosis gauge (AMG) is an independent prognostic biomarker in ICI-treated patients 📉 Low AMG is associated with shorter PFS & OS 🎯A practical, accessible, and promising biomarker 🔗 doi.org/10.1080/175074…

Huge congrats Taha Koray Sahin ! Extremely happy to see your success as a humble and dedicated young scientist. Hard work paid-off! Can't wait to see what's next! OncoAlert Deniz Can Guven Sercan Aksoy, MD Ömer Dizdar #MedX #MedTwitter #CancerResearch

🚨Just weeks after #ASCO25, the latest highlights in genitourinary cancers are now available. The newly released The ASCO Post provides a quick and concise overview. 👀Take another look, this time from our perspective w/ Yüksel Ürün 👉bit.ly/46lgtHK ASCO

Inviting all Young Oncologists to #ESMOYOC sessions at #ESMOGI25 Starting today with Mentorship Session with three great speakers at 12:45 ESMO - Eur. Oncology OncoDaily Jakob Nikolas Kather Rodrigo Sánchez-Bayona Elene Mariamidze Liz Connolly Pawel Sobczuk Myrto K. Moutafi Hongcheng Zhu 祝鸿程 Saad Nasir, MD Pablo Mando

We continue #ESMOYOC activities at #ESMOGI25 today at 12:45pm ⏱️⏱️ We have 3️⃣ great speakers to discuss building a career in GI oncology 💯💯 Expecting all YOs to join for valuable insights ✅✅ ESMO - Eur. Oncology OncoDaily Arndt Vogel Rachel Riechelmann Josep Tabernero Rille

Arndt Vogel #ESMOGI25 value of using social media in research

tandfonline.com/eprint/D7EVPHK… 🆕Our latest study is now out in Experts Review of Anti Cancer Therapy. 🧠ICIs appear safe in patients with chronic hepatitis B 📉 Of the 65 patients, 15 (23.0%) experienced irAEs of Grade 1–2. 1 (1.5%) patient had grade 3 pneumonitis